Patexia Research

Case number 2:18-cv-11518

Lawsuits

CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. et al > Summary

Court Case Number 2:18-cv-11518

Filing Date Jul 10, 2018

Termination Date Mar 29, 2019

Court New Jersey District Court

Status Judgment - Judgment on Consent

JudgesSusan D. Wigenton, Leda D. Wettre

Plaintiff

Defendant

2

LOTUS PHARMACEUTICAL CO., LTD.

Plaintiff Attorneys

16

Celgene
Attorney Name: William C. Baton
Saul Ewing LLP

Celgene
Attorney Name: Frank C. Calvosa
Quinn Emanuel Urquhart & Sullivan

Celgene
Attorney Name: Brian Forsatz
Quinn Emanuel Urquhart & Sullivan

Celgene
Attorney Name: Charles M. Lizza
Saul Ewing LLP

Celgene
Attorney Name: David Leigh Moses
Saul Ewing LLP

Celgene
Attorney Name: Sarah A. Sullivan
Saul Ewing LLP

Celgene
Attorney Name: Dominic Cerrito
Quinn Emanuel Urquhart & Sullivan

Celgene
Attorney Name: Eric C. Stops
Quinn Emanuel Urquhart & Sullivan

Celgene
Attorney Name: Andrew S. Chalson
Quinn Emanuel Urquhart & Sullivan

Celgene
Attorney Name: Anthony M. Insogna
Jones Day

Celgene
Attorney Name: Cary Miller
Jones Day

Celgene
Attorney Name: Matthew J. Hertko
Jones Day

Celgene
Attorney Name: Evangeline L. Shih
Quinn Emanuel Urquhart & Sullivan

Celgene
Attorney Name: Steven J. Corr
Jones Day

Celgene
Attorney Name: Gabriel P. Brier
Quinn Emanuel Urquhart & Sullivan

Celgene
Attorney Name: Marta A. Godecki
Quinn Emanuel Urquhart & Sullivan

Defendant Attorneys

6

LOTUS PHARMACEUTICAL CO., LTD.
Attorney Name: Aaron S. Eckenthal
Lerner David LLP

LOTUS PHARMACEUTICAL CO., LTD.
Attorney Name: William L. Mentlik
Lerner David LLP

LOTUS PHARMACEUTICAL CO., LTD.
Attorney Name: Tedd William van Buskirk
Lerner David LLP

Alvogen
Attorney Name: Aaron S. Eckenthal
Lerner David LLP

Alvogen
Attorney Name: William L. Mentlik
Lerner David LLP

Alvogen
Attorney Name: Tedd William van Buskirk
Lerner David LLP

Counter Defendant

4

Celgene
Attorney Name: William C. Baton
Saul Ewing LLP

Celgene
Attorney Name: Charles M. Lizza
Saul Ewing LLP

Celgene
Attorney Name: David Leigh Moses
Saul Ewing LLP

Celgene
Attorney Name: Sarah A. Sullivan
Saul Ewing LLP

Counter Claimant

6

Alvogen
Attorney Name: Aaron S. Eckenthal
Lerner David LLP

Alvogen
Attorney Name: William L. Mentlik
Lerner David LLP

Alvogen
Attorney Name: Tedd William van Buskirk
Lerner David LLP

LOTUS PHARMACEUTICAL CO., LTD.
Attorney Name: Aaron S. Eckenthal
Lerner David LLP

LOTUS PHARMACEUTICAL CO., LTD.
Attorney Name: William L. Mentlik
Lerner David LLP

LOTUS PHARMACEUTICAL CO., LTD.
Attorney Name: Tedd William van Buskirk
Lerner David LLP

Cause

15:1126 Patent Infringement

Related Patents

Doc No	Title	Issue date
08431598	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione	Apr 30, 2013
08315886	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Nov 20, 2012
08193219	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione	Jun 5, 2012
07977357	Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindo1-2-yl)-piperidine-2,6-dione	Jul 12, 2011
07968569	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione	Jun 28, 2011
07855217	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione	Dec 21, 2010
07465800	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione	Dec 16, 2008
07189740	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes	Mar 13, 2007
06755784	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Jun 29, 2004
06561977	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	May 13, 2003
06315720	Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug	Nov 13, 2001